VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only commercially-approved trivalent hepatitis B vaccine, Sci-B-Vac®, which is approved for use in Israel and 10 other countries and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. Integrating its cytomegalovirus (CMV) expertise with the eVLP platform technology, VBI’s lead eVLP program candidates include a prophylactic CMV vaccine candidate and a glioblastoma (GBM) vaccine immunotherapeutic candidate. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Phone: +1 617-830-3031
Total raised: $50M
Founded date: 2001
Investors 4
Date | Name | Website |
- | 5AM Ventur... | 5amventure... |
17.07.2021 | ARCH Ventu... | archventur... |
- | K2 HealthV... | k2healthve... |
- | Perceptive... | perceptive... |
Funding Rounds 1
Date | Series | Amount | Investors |
27.05.2020 | - | $50M | - |
Mentions in press and media 24
Date | Title | Description | Source |
22.03.2024 | Brii Biosciences Provides Corporate Update and Reports Full-... | Transitioning HBV cure programs into multiple late-stage combination studies with interim results th... | en.prnasia... |
27.12.2021 | Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial o... | DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio&quo... | en.prnasia... |
09.12.2021 | VBI Vaccines : Announces Filing of New Drug Submission for 3... | VBI Vaccines Announces Filing of New Drug Submission for 3-Antigen Hepatitis B Vaccine to Health Can... | marketscre... |
02.12.2021 | VBI Vaccines : to Present New Overall Survival Data from Pha... | VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World ... | marketscre... |
01.12.2021 | VBI Vaccines : Announces FDA Approval of PreHevbrio™ for the... | VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults - Pre... | marketscre... |
08.11.2021 | VBI Vaccines Announces Third Quarter 2021 Financial Results ... | VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatiti... | marketscre... |
01.11.2021 | VBI Vaccines Announces e-Poster Presentation of 3-Antigen Pr... | VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at T... | marketscre... |
14.10.2021 | VBI Vaccines : Announces Publication of Results from Pivotal... | VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the purs... | marketscre... |
13.10.2021 | VBI Vaccines : Press Release dated October 13, 2021 (furnish... | Exhibit 99.1 VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of ... | marketscre... |
29.09.2021 | VBI Vaccines : Announces New Preclinical Data and Initiation... | VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broa... | marketscre... |
Show more